Skip to main content
Premium Trial:

Request an Annual Quote

Bionano Genomics: Hannah Mamuszka, Yvonne Linney, Junfeng Wang

Bionano Genomics has added Hannah Mamuszka and Yvonne Linney to its board of directors. Junfeng Wang, who joined the board as a representative of Legend Capital, has resigned from the board.

Mamuszka is the founder and CEO of Alva 10, an advisor on reimbursement for diagnostic testing. Prior to that, she was VP of Business Development and Clinical Strategy at Exosome Diagnostics. She has also held leadership positions at Asuragen, Oncotech, and Millennium Pharmaceuticals. She holds a master's degree in molecular biology from Harvard University.

Yvonne Linney is the founder of Linney BioConsulting. She has also served as CEO of Transcriptic, now operating as Strateos, where she was also COO and served on the board, and served in executive positions at Agilent Technologies, Bayer Diagnostics, and Caliper Life Sciences. She holds a doctorate in genetics from Leicester University in the UK.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.